Breast Imaging

Why Is Routine Systemic Imaging Not Recommended for Breast Cancer Surveillance?

·
Why Is Routine Systemic Imaging Not Recommended for Breast Cancer Surveillance?

A 58-year-old woman with a history of Stage IIB invasive ductal carcinoma, now five years post-treatment, presents for her annual oncology follow-up. She feels well and has no new complaints but expresses anxiety about potential recurrence, asking if she should get a “full-body scan just to be sure.” This common clinical question places you at a critical decision point: ordering surveillance imaging for distant metastatic disease in an asymptomatic patient. This article details the evidence-based workflow for this specific scenario, explaining why major clinical guidelines advise against this practice. For the evaluation of distant metastatic disease during routine surveillance in an asymptomatic patient, the American College of Radiology (ACR) rates systemic imaging modalities like PET/CT, CT, and bone scans as Usually Not Appropriate.

Who Fits This Clinical Scenario?

This guidance applies to a specific and common patient population: individuals with a history of invasive breast cancer, regardless of their original clinical stage, who are now in the surveillance phase of their care and are asymptomatic. The key elements defining this scenario are:

  • A prior diagnosis of invasive breast cancer has been treated with curative intent.
  • The patient is currently undergoing routine follow-up (surveillance).
  • The patient has no new or persistent signs or symptoms concerning for metastatic disease (e.g., new focal bone pain, persistent cough, unexplained weight loss, jaundice, or focal neurological deficits).
  • The clinical question is specifically whether to perform imaging to screen for distant (systemic) metastases.

This workflow is distinct from other related clinical situations. It does not apply to patients who present with new, concerning symptoms that require a diagnostic workup. For example, a patient with new, severe rib pain would trigger a targeted evaluation for bone metastases, a different clinical pathway. Similarly, this guidance for distant disease surveillance should not be confused with surveillance for local recurrence in the breast or chest wall, which is typically performed with annual mammography and is considered a standard of care.

What Are the Clinical Considerations in Surveillance?

In the context of asymptomatic surveillance, the primary goal is the early detection of distant metastatic disease with the hope of improving long-term outcomes. Breast cancer most commonly metastasizes to the bones, lungs, liver, and brain. While the desire to find a potential recurrence before it becomes symptomatic is understandable for both patients and clinicians, the decision to order imaging must be weighed against the evidence and potential harms.

The central issue is the low pre-test probability of finding actionable, isolated metastatic disease in a patient who feels entirely well. Routine systemic imaging in this population has a low diagnostic yield. Instead, it frequently uncovers incidental, benign findings—such as liver hemangiomas, adrenal adenomas, or degenerative changes in the spine—that can be indistinguishable from metastases on initial imaging. These indeterminate findings often trigger a cascade of further tests, including additional imaging, biopsies, and specialist consultations, which generate significant patient anxiety, costs, and potential procedural complications, all without a proven survival benefit.

Why Is Routine Systemic Imaging Usually Not Appropriate for Surveillance?

The ACR Appropriateness Criteria, along with guidelines from the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN), consistently recommend against routine systemic imaging for distant metastases in asymptomatic breast cancer survivors. The rationale is multifactorial, grounded in the lack of evidence for improved outcomes and the clear potential for harm.

For this specific scenario, the ACR rates all major systemic imaging modalities as Usually Not Appropriate. This includes:

  • FDG-PET/CT skull base to mid-thigh: While highly sensitive for metastatic disease, PET/CT has a significant rate of false-positive findings in a low-prevalence (asymptomatic) population. It also carries a substantial radiation dose (ACR Relative Radiation Level ☢☢☢☢, 10-30 mSv).
  • CT chest, abdomen, and pelvis with IV contrast: Similar to PET/CT, this study has a low yield in asymptomatic patients and can reveal numerous incidentalomas. The cumulative radiation exposure from annual scans is considerable (ACR RRL ☢☢☢☢, 10-30 mSv).
  • Bone scan whole body: This modality is sensitive for osseous metastases but is notoriously nonspecific, as uptake can be seen with fractures, arthritis, and other benign bone conditions, leading to further workup. The radiation dose is also a factor (ACR RRL ☢☢☢, 1-10 mSv).

Even a non-radiation modality like axillary ultrasound (US axilla) is rated Usually Not Appropriate for the evaluation of distant metastatic disease. Its utility is in assessing locoregional nodal status, which is a different clinical question from systemic surveillance. The consensus from multiple large-scale studies and clinical trials is that intensive imaging surveillance does not improve overall survival, disease-free survival, or quality of life compared to a strategy of performing imaging only when a patient develops symptoms.

What’s Next? The Downstream Workflow for Asymptomatic Surveillance

The appropriate downstream workflow for an asymptomatic patient in breast cancer surveillance is centered on clinical vigilance rather than routine imaging. The focus should be on a structured follow-up schedule that includes a careful history and physical examination.

  • If the patient remains asymptomatic: The recommended course is to continue regular clinical follow-ups as per established guidelines (e.g., every 3-6 months for the first few years, then annually). This includes a thorough review of systems to screen for any new, persistent symptoms. Patient education is paramount, empowering them to recognize and report concerning symptoms promptly.
  • If the patient develops new, concerning symptoms: This is the critical trigger to shift from a surveillance to a diagnostic pathway. The clinical scenario changes, and imaging becomes appropriate. The choice of study should be targeted to the specific symptom. For example:
    • New, localized bone pain warrants a bone scan and/or targeted radiographs or MRI.
    • A persistent, non-productive cough or dyspnea would prompt a chest X-ray or CT of the chest.
    • New-onset jaundice or right upper quadrant pain would lead to an abdominal ultrasound or CT.
    • New, focal neurological symptoms like seizures or persistent headaches would trigger a brain MRI.

This symptom-driven approach ensures that the diagnostic power of imaging is deployed when the pre-test probability of disease is higher, maximizing its value and minimizing the harms of low-yield screening.

Pitfalls to Avoid (and When to Escalate)

Navigating breast cancer surveillance requires avoiding several common pitfalls. A primary pitfall is ordering surveillance imaging due to patient anxiety or habit, contrary to evidence-based guidelines. This can initiate a cascade of unnecessary and potentially harmful interventions. Another significant error is dismissing a patient’s new, persistent, and localized symptom as insignificant. The key is to differentiate vague, fleeting complaints from a clear clinical change that warrants a diagnostic workup.

Finally, do not misinterpret the guidelines as a prohibition on all imaging. They apply strictly to the asymptomatic surveillance setting. If a patient develops credible signs or symptoms of metastatic disease, the appropriate escalation is to immediately initiate a targeted diagnostic imaging workup.

Related ACR Topics and Tools

This article covers a single, specific scenario within the broader topic of imaging for invasive breast cancer. For a comprehensive overview of other clinical presentations, from initial diagnosis to locoregional staging, please consult our parent guide. The following GigHz tools can also support your clinical decision-making:

Frequently Asked Questions

Does this ‘no routine imaging’ recommendation apply even to patients with a history of Stage III breast cancer?

Yes. The current ACR, ASCO, and NCCN guidelines for surveillance of distant metastases apply to asymptomatic patients regardless of their original cancer stage. The evidence has not shown a survival benefit for routine systemic imaging even in higher-risk populations.

My patient is very anxious and insists on a scan for peace of mind. How should I handle this?

This is a common and challenging situation. The best approach is patient counseling. Discuss the lack of proven survival benefit and explain the significant risks of false-positive results, which can lead to a cascade of further tests, biopsies, and heightened anxiety. Frame the conversation around a partnership focused on vigilant symptom monitoring as the most effective, evidence-based strategy.

What about using serum tumor markers like CA 15-3 or CA 27-29 for surveillance?

Major oncology guidelines, including those from ASCO, do not recommend the routine use of serum tumor markers for breast cancer surveillance. Similar to imaging, they have low sensitivity and specificity in asymptomatic patients and can lead to false positives and unnecessary workups without a demonstrated impact on survival.

What is the difference between surveillance for local recurrence versus distant recurrence?

This is a critical distinction. Surveillance for local recurrence (in the treated breast, chest wall, or regional lymph nodes) is a standard of care and is primarily done with annual mammography. This article’s guidance applies specifically to surveillance for distant (systemic) recurrence in other parts of the body, like the bones, liver, or lungs, for which routine imaging is not recommended in asymptomatic patients.

If a patient develops a new, persistent headache, should I order a brain MRI?

Yes, this changes the clinical context from asymptomatic surveillance to a diagnostic workup. A new, persistent, and unexplained neurological symptom (like a severe headache, seizure, or focal weakness) warrants a thorough evaluation, which would typically include a contrast-enhanced MRI of the brain. The ‘no imaging’ rule is for screening, not for diagnosing new symptoms.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026